Literature DB >> 25682309

M2/ANXA5 haplotype as a predisposition factor in Malay women and couples experiencing recurrent spontaneous abortion: a pilot study.

Tang Thean Hock1, Nadja Bogdanova2, Ang Kai Cheen3, Sushilnathan Kathirgamanathan4, Ridzuan Bin Abdullah4, Narazah Mohd Yusoff3, Wan Zaidah Abdullah5, Faizatul Syima Abdul Manaf3, Peter Wieacker2, Arseni Markoff6.   

Abstract

Recurrent spontaneous abortion (RSA) is a prevalent condition among the Malay population of Malaysia, where carriage risk of conventional hereditary thrombophilia factors has been generally ruled out. The contribution of M2/ANXA5, a common haplotype in the annexin A5 gene promoter, was evalauted for RSA in Malay. Seventy-seven women who had experienced two or more unexplained RSA and 41 available male partners were selected for study, with 360 population controls recruited from healthy Malay individuals. Incidence of M2 carriage and odds ratios were calculated between control and patient groups, and clinically defined subgroups and RSA risk was evaluated. M2/ANXA5, found in 42.2% of the general Malay population, was associated with greater risks for women with primary and secondary RSA with early (gestational week 5-15) losses. The risk was somewhat higher in Malay couples when both partners were carriers and a trend of higher prevalence was seen for the male partners patients who had experienced RSA. M2 carriage seems to be a risk factor with unusually high incidence in Malay women and couples with primary and secondary RSA with 'early' spontaneous abortions. The associated male partner risk confirms the proposed role of M2/ANXA5 as a genetic trait impeding embryonic anticoagulation.
Copyright © 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ANXA5; M2/ANXA5; annexin A5; recurrent pregnancy loss; risk factor

Mesh:

Substances:

Year:  2015        PMID: 25682309     DOI: 10.1016/j.rbmo.2014.12.014

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  Assessment of M2/ANXA5 haplotype as a risk factor in couples with placenta-mediated pregnancy complications.

Authors:  Nina Rogenhofer; Lara R M Nienaber; Lea C Amshoff; Nadia Bogdanova; David Petroff; Peter Wieacker; Christian J Thaler; Arseni Markoff
Journal:  J Assist Reprod Genet       Date:  2017-09-13       Impact factor: 3.412

2.  Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications.

Authors:  Federico Aranda; Sebastián Udry; Silvia Perés Wingeyer; Lea Christina Amshoff; Nadja Bogdanova; Peter Wieacker; José Omar Latino; Arseni Markoff; Gabriela de Larrañaga
Journal:  J Assist Reprod Genet       Date:  2018-03-01       Impact factor: 3.412

3.  Genetic analysis of the M2/ANXA5 haplotype as recurrent pregnancy loss predisposition in the Malay population.

Authors:  Kai-Cheen Ang; Sushilnathan Kathirgamanathan; Ewe Seng Ch'ng; Yan-Yeow Lee; Anna-Liza Roslani; Bavanandan Naidu; Krishna Kumar; Ridzuan Abdullah; Siti-Nadiah Abdul Kadir; Narazah Mohd Yusoff; Wan Zaidah Abdullah; Nadja Bogdanova; Peter Wieacker; Arseni Markoff; Thean-Hock Tang
Journal:  J Assist Reprod Genet       Date:  2017-01-20       Impact factor: 3.412

Review 4.  Deficiencies in reporting results of lesbians and gays after donor intrauterine insemination and assisted reproductive technology treatments: a review of the first emerging studies.

Authors:  Juan J Tarín; Miguel A García-Pérez; Antonio Cano
Journal:  Reprod Biol Endocrinol       Date:  2015-05-29       Impact factor: 5.211

5.  Annexin A5 Promoter Haplotype M2 Is Not a Risk Factor for Recurrent Pregnancy Loss in Northern Europe.

Authors:  Liina Nagirnaja; Diana Nõmmemees; Kristiina Rull; Ole B Christiansen; Henriette S Nielsen; Maris Laan
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

6.  Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome.

Authors:  Simon Fishel; Deborah Baker; Janine Elson; Maha Ragunath; Glenn Atkinson; Adel Shaker; Ahmed Omar; Rahnuma Kazem; Ashley Beccles; Ian A Greer
Journal:  EBioMedicine       Date:  2016-07-18       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.